HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keruly, J. C. Articles by Moore, R. D. Search for Related Content PubMed PubMed Citation Articles by Keruly, J. C. Articles by Moore, R. D. Related Collections Insurance HIV/AIDS

Jeanne C. Keruly, MS, CRNP, Richard Conviser, PhD and Richard D. Moore, MD, MHSc

Jeanne C. Keruly and Richard D. Moore are with the Johns Hopkins University School of Medicine, Baltimore, Md. Richard Conviser is with the Health Resources and Services Administration, Rockville, Md.

Correspondence: Requests for reprints should be sent to Richard D. Moore, MD, Johns Hopkins University School of Medicine, 1830 E Monument Street, Room 8059, Baltimore, MD 21205 (e-mail: rdmoore{at}jhmi.edu).

Objectives. This study was designed to assess sociodemographic and medical insurer factors associated with receipt of highly active antiretroviral therapy (HAART).

Methods. Patients included (n = 959) were enrolled in the Johns Hopkins HIV Clinic after April 1, 1996, received 90 days of care, and had a CD4 count 500 cells/mm³ or HIV-1 RNA > 20 000 copies/mL. We assessed the associations of sociodemographic factors and medical insurance with receipt of HAART, stratified by 2 time periods (April 1996 through March 1997 versus April 1997 through March 1999).

Results. HAART was more likely to be used in patients who were > 39 years, White, had CD4 counts < 350 cells/mm³, had fewer missed clinic visits, and did not have intravenous drug use as their risk factor for HIV transmission. In period 1 (April 1996 through March 1997), HAART was more likely to be used in patients who were commercially insured than in other payer groups; differences between payers narrowed in period 2 (April 1997 through March 1999), however, as did differences by race.

Conclusions. Differences in use of HAART on the basis of payer have narrowed since 1996. This encouraging finding may demonstrate the importance of programs that lower economic barriers to medical care.

This article has been cited by other articles:

				K. Clements-Nolle, R. Marx, M. Pendo, E. Loughran, M. Estes, and M. Katz Highly Active Antiretroviral Therapy Use and HIV Transmission Risk Behaviors Among Individuals Who Are HIV Infected and Were Recently Released From Jail Am J Public Health, April 1, 2008; 98(4): 661 - 666. [Abstract] [Full Text] [PDF]

				C.T. Fang, Y.Y. Chang, H.M. Hsu, S.J. Twu, K.T. Chen, C.C. Lin, L.Y.L. Huang, M.Y. Chen, J.S. Hwang, J.D. Wang, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy QJM, February 1, 2007; 100(2): 97 - 105. [Abstract] [Full Text] [PDF]

				A. L. Fitzpatrick, N. R. Powe, L. S. Cooper, D. G. Ives, and J. A. Robbins Barriers to Health Care Access Among the Elderly and Who Perceives Them Am J Public Health, October 1, 2004; 94(10): 1788 - 1794. [Abstract] [Full Text] [PDF]